文献速递脑血管病

MRproANP对卒中患者的独立预后价值随时间不变

Independent Prognostic Value of MRproANP (Midregional Proatrial Natriuretic Peptide) Levels in Patients With Stroke Is Unaltered Over Time.
PubMed 文献 · Stroke · 2020-03-27

本研究在348例连续入组的急性缺血性卒中患者中,于入院(<72小时)及住院前5天多个时间点检测MRproANP,评估其对90天死亡、90天功能结局及心源性卒中病因的预后价值。结果显示MRproANP水平在初始5天内轻度下降,但对心源性卒中病因和90天死亡仍保持高度预测性,且重复测量未改善预后价值。

要点

  • MRproANP在卒中急性期至少5天内保持独立预后价值。
  • 重复测量MRproANP不改善对90天死亡和心源性病因的预测。
  • 入院时及第1、3、5天MRproANP均与心源性卒中和90天死亡显著相关。

核心结论

  • MRproANP在卒中急性期至少5天内独立预后价值不变,重复测量不改善预后价值。

研究设计与样本

  • 研究连续入组348例急性缺血性卒中患者,于入院(<72小时)及住院前5天多个时间点采集MRproANP样本。
  • 评估MRproANP对90天死亡、90天功能结局及心源性卒中病因的预后价值,并用广义估计方程建模随时间的变化。

主要发现

  • MRproANP水平在初始5天内轻度下降。
  • 对心源性卒中病因的比值比在入院、第1天、第3天和第5天分别为9.75(95%CI 3.2-29)、10.62(95%CI 3.4-33.3)、10.8(95%CI 3.1-37.1)和19.4(95%CI 5.49-68.7)。
  • 对90天死亡的比值比在入院、第1天、第3天和第5天分别为59.4(95%CI 7.4-480.7)、78.3(95%CI 7.9-772.6)、14.5(95%CI 1.4-145)和19.81(95%CI 2.7-143.4)。
  • 随时间变化未显著改变MRproANP的预后价值(多变量模型中交互项P=0.65和P=0.56)。

临床怎么用

  • 急性缺血性卒中患者入院(<72小时)或住院前5天内单次检测MRproANP即可用于心源性病因和90天死亡的风险分层。
  • 无需重复检测MRproANP来改善预后评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- MRproANP (midregional proatrial natriuretic peptide) is known to be independently associated with cardioembolic stroke cause and to improve risk stratification for 90-day mortality when measured within 24 to 72 hours after symptom onset in patients with acute ischemic stroke. However, the optimal time point for assessment remains unclear. This study aimed to evaluate prognostic utility of MRproANP at different time points during the first 5 days of hospitalization in patients with acute ischemic stroke. Methods- Samples of MRproANP were collected on admission (<72 hours after onset) and at multiple time points during the first 5 days of hospitalization in 348 consecutively enrolled patients with acute ischemic stroke. The prognostic value for 90-day mortality, 90-day functional outcome, and the association with cardioembolic stroke cause was assessed regarding the time of measurement, and change over time was modeled using generalized estimating equations. Results- MRproANP levels modestly decease over the initial 5 days but remain highly predictive for cardioembolic stroke cause (odds ratio, 9.75 [95% CI, 3.2-29]; 10.62 [95% CI, 3.4-33.3]; 10.8 [95% CI, 3.1-37.1]; 19.4 [95% CI, 5.49-68.7] on admission, day 1, 3 and 5) and 90-day mortality (odds ratio, 59.4 [95% CI, 7.4-480.7]; 78.3 [95% CI, 7.9-772.6]; 14.5 [95% CI, 1.4-145]; 19.81 [95% CI, 2.7-143.4] on admission, day 1, 3, and 5). Change over time does not significantly modify the prognostic value of MRproANP (P=0.65 and P=0.56 for the interaction term in the multivariate model). Conclusions- Independent prognostic value of MRproANP remains unaltered in the acute phase of stroke at least up to 5 days; repeated measurements do not improve the prognostic value.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Arnold M, Nakas C, Luft A, et al. Independent Prognostic Value of MRproANP (Midregional Proatrial Natriuretic Peptide) Levels in Patients With Stroke Is Unaltered Over Time. Stroke. 2020. PMID: 32216532. doi:10.1161/STROKEAHA.120.029333

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。